Insulet (PODD) Stock Forecast, Price Target & Predictions
PODD Stock Forecast
Insulet stock forecast is as follows: an average price target of $268.60 (represents a 14.85% upside from PODD’s last price of $233.87) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
PODD Price Target
The average price target for Insulet (PODD) is $268.60 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $350.00 to $200.00. This represents a potential 14.85% upside from PODD's last price of $233.87.
PODD Analyst Ratings
According to 16 Wall Street analysts, Insulet's rating consensus is 'Buy'. The analyst rating breakdown for PODD stock is 0 'Strong Buy' (0.00%), 14 'Buy' (87.50%), 2 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Insulet Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 27, 2024 | Matt O'Brien | Piper Sandler | $230.00 | $193.51 | 18.85% | -1.65% |
| Aug 27, 2024 | Steven Lichtman | Oppenheimer | $233.00 | $193.54 | 20.39% | -0.37% |
| Aug 27, 2024 | Matthew Taylor | Jefferies | $260.00 | $193.54 | 34.34% | 11.17% |
| Aug 09, 2024 | Marie Thibault | BTIG | $250.00 | $199.79 | 25.13% | 6.90% |
| May 13, 2024 | Matt Miksic | Barclays | $200.00 | $165.90 | 20.55% | -14.48% |
| May 07, 2024 | Mike Polark | Wolfe Research | $200.00 | $176.40 | 13.38% | -14.48% |
| Mar 21, 2024 | Kyle Rose | Canaccord Genuity | $226.00 | $166.64 | 35.62% | -3.37% |
| Jan 06, 2023 | - | Morgan Stanley | $320.00 | $295.00 | 8.47% | 36.83% |
| Nov 03, 2022 | Matt O'Brien | Piper Sandler | $340.00 | $255.35 | 33.15% | 45.38% |
| Oct 17, 2022 | Cecilia Furlong | Morgan Stanley | $273.00 | $224.16 | 21.79% | 16.73% |
The latest Insulet stock forecast, released on Aug 27, 2024 by Matt O'Brien from Piper Sandler, set a price target of $230.00, which represents a 18.85% increase from the stock price at the time of the forecast ($193.51), and a -1.65% decrease from PODD last price ($233.87).
Insulet Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 4 | 7 |
| Avg Price Target | $241.00 | $243.25 | $228.43 |
| Last Closing Price | $233.87 | $233.87 | $233.87 |
| Upside/Downside | 3.05% | 4.01% | -2.33% |
In the current month, the average price target of Insulet stock is $241.00, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 3.05% increase as opposed to Insulet's last price of $233.87. This month's average price target is down -0.92% compared to last quarter, and up 5.50% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 27, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 27, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 12, 2024 | UBS | Buy | Buy | Hold |
| Aug 12, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Aug 11, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 09, 2024 | BTIG | Buy | Buy | Hold |
| Aug 09, 2024 | UBS | Neutral | Neutral | Hold |
| Jul 23, 2024 | Wolfe Research | Buy | Buy | Hold |
Insulet's last stock rating was published by Piper Sandler on Aug 27, 2024. The company gave PODD a "Overweight" rating, the same as its previous rate.
Insulet Financial Forecast
Insulet Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $432.70M | $396.50M | $358.10M | $369.70M | $340.80M | $299.40M | $295.40M | $307.70M | $275.60M | $263.20M | $252.30M | $246.10M | $234.00M | $226.30M | $198.00M | $209.39M | $192.12M |
| Avg Forecast | $766.31M | $707.75M | $669.98M | $639.33M | $670.33M | $611.63M | $568.84M | $536.37M | $567.54M | $518.76M | $488.00M | $424.05M | $461.26M | $414.32M | $385.26M | $330.91M | $332.45M | $312.11M | $291.45M | $288.02M | $299.33M | $272.62M | $258.88M | $247.53M | $232.90M | $221.72M | $212.41M | $189.44M | $199.51M | $179.49M |
| High Forecast | $772.08M | $713.08M | $675.02M | $644.14M | $675.38M | $616.23M | $573.12M | $540.40M | $571.81M | $521.26M | $491.67M | $427.24M | $467.11M | $419.27M | $388.16M | $333.40M | $334.95M | $314.45M | $293.76M | $290.30M | $301.71M | $274.78M | $260.93M | $249.49M | $234.74M | $223.48M | $214.09M | $190.94M | $201.09M | $180.92M |
| Low Forecast | $761.36M | $703.18M | $665.65M | $635.20M | $666.00M | $607.68M | $565.17M | $532.90M | $563.88M | $516.06M | $484.85M | $421.31M | $456.38M | $406.12M | $382.77M | $328.77M | $330.30M | $310.09M | $286.51M | $283.13M | $294.25M | $267.99M | $254.49M | $243.32M | $228.94M | $217.96M | $208.80M | $186.22M | $196.12M | $176.45M |
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.03% | 1.08% | 1.11% | 1.09% | 1.03% | 1.03% | 1.03% | 1.01% | 1.02% | 1.02% | 1.06% | 1.06% | 1.07% | 1.05% | 1.05% | 1.07% |
Insulet's average Quarter revenue forecast for Dec 23 based on 9 analysts is $461.26M, with a low forecast of $456.38M, and a high forecast of $467.11M. PODD's average Quarter revenue forecast represents a 6.60% increase compared to the company's last Quarter revenue of $432.70M (Sep 23).
Insulet EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $55.50M | $31.10M | $27.50M | $25.00M | $1.10M | $-27.80M | $38.20M | $62.60M | $45.20M | $2.40M | $25.90M | $19.20M | $35.50M | $38.40M | $17.20M | $26.14M | $17.56M |
| Avg Forecast | $61.13M | $56.46M | $53.45M | $51.00M | $53.47M | $48.79M | $45.38M | $42.79M | $45.27M | $41.38M | $38.93M | $61.46M | $36.80M | $33.05M | $30.73M | $55.87M | $26.52M | $54.24M | $23.25M | $50.79M | $23.88M | $21.75M | $20.65M | $46.62M | $18.58M | $20.00M | $16.94M | $15.11M | $15.92M | $14.32M |
| High Forecast | $61.59M | $56.88M | $53.85M | $51.38M | $53.88M | $49.16M | $45.72M | $43.11M | $45.62M | $41.58M | $39.22M | $73.75M | $37.26M | $33.45M | $30.96M | $67.04M | $26.72M | $65.09M | $23.43M | $60.95M | $24.07M | $21.92M | $20.82M | $55.94M | $18.73M | $24.00M | $17.08M | $15.23M | $16.04M | $14.43M |
| Low Forecast | $60.74M | $56.09M | $53.10M | $50.67M | $53.13M | $48.48M | $45.08M | $42.51M | $44.98M | $41.17M | $38.68M | $49.17M | $36.41M | $32.40M | $30.53M | $44.70M | $26.35M | $43.39M | $22.86M | $40.63M | $23.47M | $21.38M | $20.30M | $37.30M | $18.26M | $16.00M | $16.66M | $14.86M | $15.64M | $14.08M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.68% | 1.01% | 0.49% | 0.94% | 0.02% | -1.20% | 0.75% | 2.62% | 2.08% | 0.12% | 0.56% | 1.03% | 1.77% | 2.27% | 1.14% | 1.64% | 1.23% |
9 analysts predict PODD's average Quarter EBITDA for Dec 23 to be $36.80M, with a high of $37.26M and a low of $36.41M. This is -33.70% lower than Insulet's previous annual EBITDA (Sep 23) of $55.50M.
Insulet Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $51.90M | $27.30M | $23.80M | $17.00M | $-5.20M | $-35.00M | $27.80M | $29.20M | $12.60M | $-25.00M | - | $-17.10M | $11.60M | $14.40M | $-2.10M | $4.97M | $852.00K |
| Avg Forecast | $110.81M | $94.22M | $77.59M | $74.14M | $90.51M | $73.44M | $60.45M | $56.49M | $75.65M | $58.14M | $41.61M | $32.54M | $48.19M | $29.74M | $19.37M | $29.58M | $16.18M | $15.12M | $16.58M | $26.90M | $23.14M | $18.31M | $9.94M | $5.35M | $-2.94M | $6.54M | $155.06K | $-406.80K | $8.03M | $2.55M |
| High Forecast | $111.90M | $95.14M | $78.35M | $74.87M | $91.40M | $74.16M | $61.04M | $57.05M | $76.39M | $69.32M | $42.01M | $39.05M | $58.26M | $40.89M | $19.56M | $35.50M | $16.34M | $18.14M | $16.75M | $32.27M | $23.38M | $18.49M | $10.04M | $5.40M | $-2.88M | $7.84M | $156.66K | $-397.82K | $8.12M | $2.58M |
| Low Forecast | $109.88M | $93.43M | $76.94M | $73.52M | $89.75M | $72.82M | $59.94M | $56.02M | $75.01M | $52.17M | $41.26M | $26.03M | $38.84M | $19.33M | $19.21M | $23.67M | $16.05M | $12.10M | $16.21M | $21.52M | $22.63M | $17.90M | $9.72M | $5.23M | $-2.97M | $5.23M | $151.63K | $-410.99K | $7.86M | $2.49M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75% | 1.41% | 0.80% | 1.05% | -0.34% | -2.11% | 1.03% | 1.26% | 0.69% | -2.52% | - | 5.81% | 1.77% | 92.87% | 5.16% | 0.62% | 0.33% |
Insulet's average Quarter net income forecast for Dec 23 is $48.19M, with a range of $38.84M to $58.26M. PODD's average Quarter net income forecast represents a -7.14% decrease compared to the company's last Quarter net income of $51.90M (Sep 23).
Insulet SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $180.70M | $178.70M | $162.70M | $144.30M | $140.40M | $174.40M | $128.70M | $121.70M | $117.50M | $116.30M | $110.50M | $130.10M | $89.20M | $80.80M | $83.90M | $81.28M | $75.30M |
| Avg Forecast | $327.87M | $302.81M | $286.65M | $273.54M | $286.80M | $261.69M | $243.38M | $229.48M | $242.82M | $221.95M | $208.79M | $150.66M | $197.35M | $177.27M | $164.83M | $136.96M | $142.24M | $141.00M | $124.70M | $124.51M | $128.07M | $116.64M | $110.76M | $198.90M | $99.64M | $50.26M | $90.88M | $81.05M | $85.36M | $76.80M |
| High Forecast | $330.33M | $305.09M | $288.81M | $275.60M | $288.96M | $263.65M | $245.21M | $231.21M | $244.65M | $223.02M | $210.36M | $180.79M | $199.85M | $179.38M | $166.07M | $164.35M | $143.31M | $169.20M | $125.69M | $149.41M | $129.08M | $117.56M | $111.64M | $238.68M | $100.43M | $60.31M | $91.60M | $81.69M | $86.03M | $77.40M |
| Low Forecast | $325.75M | $300.85M | $284.80M | $271.77M | $284.95M | $259.99M | $241.81M | $228.00M | $241.25M | $220.79M | $207.44M | $120.53M | $195.26M | $173.76M | $163.77M | $109.57M | $141.32M | $112.80M | $122.58M | $99.61M | $125.90M | $114.66M | $108.88M | $159.12M | $97.95M | $40.21M | $89.34M | $79.67M | $83.91M | $75.49M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.08% | 1.19% | 1.01% | 1.00% | 1.40% | 1.03% | 0.95% | 1.01% | 1.05% | 0.56% | 1.31% | 1.77% | 0.89% | 1.04% | 0.95% | 0.98% |
Insulet's average Quarter SG&A projection for Dec 23 is $197.35M, based on 9 Wall Street analysts, with a range of $195.26M to $199.85M. The forecast indicates a 9.21% rise compared to PODD last annual SG&A of $180.70M (Sep 23).
Insulet EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 4 | 9 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 15 | 9 | 9 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.74 | $0.39 | $0.34 | $0.25 | $-0.07 | $-0.50 | $0.40 | $0.42 | $0.18 | $-0.37 | - | $-0.26 | $0.18 | $0.22 | $-0.03 | $0.08 | $0.01 |
| Avg Forecast | $1.50 | $1.28 | $1.05 | $1.00 | $1.23 | $1.00 | $0.82 | $0.77 | $1.03 | $0.79 | $0.56 | $0.40 | $0.65 | $0.40 | $0.26 | $0.11 | $0.22 | $0.15 | $0.22 | $0.23 | $0.31 | $0.25 | $0.13 | $0.07 | $-0.04 | $0.08 | - | $-0.01 | $0.11 | $0.03 |
| High Forecast | $1.52 | $1.29 | $1.06 | $1.01 | $1.24 | $1.00 | $0.83 | $0.77 | $1.04 | $0.94 | $0.57 | $0.41 | $0.79 | $0.55 | $0.27 | $0.11 | $0.22 | $0.15 | $0.23 | $0.23 | $0.32 | $0.25 | $0.14 | $0.07 | $-0.04 | $0.08 | - | $-0.01 | $0.11 | $0.03 |
| Low Forecast | $1.49 | $1.27 | $1.04 | $1.00 | $1.22 | $0.99 | $0.81 | $0.76 | $1.02 | $0.71 | $0.56 | $0.40 | $0.53 | $0.26 | $0.26 | $0.11 | $0.22 | $0.15 | $0.22 | $0.23 | $0.31 | $0.24 | $0.13 | $0.07 | $-0.04 | $0.08 | - | $-0.01 | $0.11 | $0.03 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.84% | 1.49% | 3.20% | 1.14% | -0.49% | -2.23% | 1.72% | 1.34% | 0.73% | -2.75% | - | 6.52% | 2.30% | 104.71% | 5.44% | 0.73% | 0.29% |
According to 9 Wall Street analysts, Insulet's projected average Quarter EPS for Dec 23 is $0.65, with a low estimate of $0.53 and a high estimate of $0.79. This represents a -11.76% decrease compared to PODD previous annual EPS of $0.74 (Sep 23).
Insulet Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IART | Integra LifeSciences | $17.47 | $43.25 | 147.57% | Sell |
| ALGN | Align | $243.73 | $554.38 | 127.46% | Buy |
| TNDM | Tandem Diabetes Care | $43.97 | $84.44 | 92.04% | Buy |
| INMD | InMode | $17.04 | $31.40 | 84.27% | Hold |
| NARI | Inari Medical | $46.52 | $72.88 | 56.66% | Buy |
| EW | Edwards Lifesciences | $68.52 | $97.09 | 41.70% | Buy |
| MASI | Masimo | $112.80 | $158.40 | 40.43% | Buy |
| DXCM | DexCom | $69.51 | $81.86 | 17.77% | Buy |
| PEN | Penumbra | $186.94 | $218.89 | 17.09% | Hold |
| INSP | Inspire Medical Systems | $203.99 | $237.80 | 16.57% | Buy |
| PODD | Insulet | $233.87 | $268.60 | 14.85% | Buy |
| ABT | Abbott Laboratories | $116.40 | $129.50 | 11.25% | Buy |
| TMDX | TransMedics Group | $151.42 | $156.86 | 3.59% | Buy |
| SYK | Stryker | $370.25 | $305.00 | -17.62% | Buy |
| GKOS | Glaukos | $126.28 | $101.56 | -19.58% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
PODD Forecast FAQ
Is Insulet a good buy?
Yes, according to 16 Wall Street analysts, Insulet (PODD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 87.50% of PODD's total ratings.
What is PODD's price target?
Insulet (PODD) average price target is $268.6 with a range of $200 to $350, implying a 14.85% from its last price of $233.87. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Insulet stock go up soon?
According to Wall Street analysts' prediction for PODD stock, the company can go up by 14.85% (from the last price of $233.87 to the average price target of $268.6), up by 49.66% based on the highest stock price target, and down by -14.48% based on the lowest stock price target.
Can Insulet stock reach $400?
PODD's average twelve months analyst stock price target of $268.6 does not support the claim that Insulet can reach $400 in the near future.
What is Insulet's current price target trend?
3 Wall Street analysts forecast a $241 price target for Insulet (PODD) this month, up 3.05% from its last price of $233.87. Compared to the last 3 and 12 months, the average price target increased by 4.01% and decreased by -2.33%, respectively.
What are Insulet's analysts' financial forecasts?
Insulet's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.39B (high $2.41B, low $2.37B), average EBITDA is $190.43M (high $191.86M, low $189.2M), average net income is $280.89M (high $283.64M, low $278.53M), average SG&A $1.02B (high $1.03B, low $1.01B), and average EPS is $3.81 (high $3.84, low $3.77). PODD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.78B (high $2.8B, low $2.77B), average EBITDA is $222.04M (high $223.71M, low $220.6M), average net income is $356.77M (high $360.26M, low $353.77M), average SG&A $1.19B (high $1.2B, low $1.18B), and average EPS is $4.83 (high $4.88, low $4.79).
Did the PODD's actual financial results beat the analysts' financial forecasts?
Based on Insulet's last annual report (Dec 2022), the company's revenue was $1.31B, beating the average analysts forecast of $1.22B by 6.64%. Apple's EBITDA was $36.5M, missing the average prediction of $154.8M by -76.42%. The company's net income was $4.6M, missing the average estimation of $74.77M by -93.85%. Apple's SG&A was $587.8M, beating the average forecast of $532.45M by 10.40%. Lastly, the company's EPS was $0.07, missing the average prediction of $0.828 by -91.55%. In terms of the last quarterly report (Sep 2023), Insulet's revenue was $432.7M, beating the average analysts' forecast of $414.32M by 4.44%. The company's EBITDA was $55.5M, beating the average prediction of $33.05M by 67.92%. Insulet's net income was $51.9M, beating the average estimation of $29.74M by 74.50%. The company's SG&A was $180.7M, beating the average forecast of $177.27M by 1.94%. Lastly, the company's EPS was $0.74, beating the average prediction of $0.403 by 83.63%